Article
Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma.
Acta oncologica (Stockholm, Sweden) - 1 Jun 2013
Spindler Karen-Lise G, Sorensen Morten M, Pallisgaard Niels, Andersen Rikke F, Havelund Birgitte M, Ploen John, Lassen Ulrik, Jakobsen Anders K M
Abstract excerpt
BACKGROUND: Patients with chemotherapy refractory metastatic colorectal cancer and KRAS mutations have no effective treatment option. The present study evaluated the efficacy of temsirolimus in chemotherapy refractory mCRC with KRAS mutations. Furthermore, we wanted to investigate if resistance to temsirolimus could be reversed by the addition of irinotecan. Finally, we analyzed pre-treatment blood samples for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.